Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives

Hasan Tahir,1,2 Arumugam Moorthy,3 Antoni Chan4 1Royal Free London NHS Trust, London, UK; 2Division of Medicine, University College London, London, UK; 3University Hospitals of Leicester NHS Trust, Leicester, UK; 4Royal Berkshire NHS Trust, Reading, UKCorrespondence: Hasan TahirRoyal Free London NHS...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tahir H, Moorthy A, Chan A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	ankylosing spondylitis secukinumab patient-reported outcomes Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/8851a219e8d84ce2863bdcb761cfbb27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8851a219e8d84ce2863bdcb761cfbb27
record_format	dspace
spelling	oai:doaj.org-article:8851a219e8d84ce2863bdcb761cfbb272021-12-02T11:21:46ZImpact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives1179-156Xhttps://doaj.org/article/8851a219e8d84ce2863bdcb761cfbb272020-11-01T00:00:00Zhttps://www.dovepress.com/impact-of-secukinumab-on-patient-reported-outcomes-in-the-treatment-of-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XHasan Tahir,1,2 Arumugam Moorthy,3 Antoni Chan4 1Royal Free London NHS Trust, London, UK; 2Division of Medicine, University College London, London, UK; 3University Hospitals of Leicester NHS Trust, Leicester, UK; 4Royal Berkshire NHS Trust, Reading, UKCorrespondence: Hasan TahirRoyal Free London NHS Trust, London, UKEmail hasan.tahir@nhs.netAbstract: Ankylosing spondylitis (AS) is a chronic rheumatic disease involving inflammation of the joints and spine, which carries a substantial, life-long burden for the patient. Secukinumab is a fully human anti-interleukin-17A monoclonal antibody, approved in the USA and EU for the treatment of AS. In this narrative review, we searched PubMed with the aim of consolidating the recent literature regarding the impact of secukinumab on patient-reported outcomes in patients with AS. A large clinical trial program has demonstrated the efficacy of secukinumab in relieving the signs and symptoms of AS. Most importantly from a patient perspective, secukinumab has produced improvements in a range of patient-reported outcomes (PROs), including pain, fatigue, quality of life and work productivity, as well as composite measures including patient-reported elements, such as the Bath indices and Assessment of SpondyloArthritis international Society (ASAS) response criteria. Benefits to patients were rapid, and sustained in the long term (up to 5 years). The positive effect of secukinumab was seen regardless of whether patients had previously been treated with anti-tumor necrosis factor (TNF) therapies. Greater improvements in PROs were associated with patients being anti-TNF-naïve, of a younger age, with shorter disease duration and higher objective measures of inflammation at baseline. The available real-world evidence suggests that the effects of secukinumab on PROs in clinical practice are consistent with those seen in clinical trials, and evidence in a real-world setting continues to be collected.Keywords: ankylosing spondylitis, secukinumab, patient-reported outcomesTahir HMoorthy AChan ADove Medical Pressarticleankylosing spondylitissecukinumabpatient-reported outcomesDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 12, Pp 277-292 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	ankylosing spondylitis secukinumab patient-reported outcomes Diseases of the musculoskeletal system RC925-935
spellingShingle	ankylosing spondylitis secukinumab patient-reported outcomes Diseases of the musculoskeletal system RC925-935 Tahir H Moorthy A Chan A Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
description	Hasan Tahir,1,2 Arumugam Moorthy,3 Antoni Chan4 1Royal Free London NHS Trust, London, UK; 2Division of Medicine, University College London, London, UK; 3University Hospitals of Leicester NHS Trust, Leicester, UK; 4Royal Berkshire NHS Trust, Reading, UKCorrespondence: Hasan TahirRoyal Free London NHS Trust, London, UKEmail hasan.tahir@nhs.netAbstract: Ankylosing spondylitis (AS) is a chronic rheumatic disease involving inflammation of the joints and spine, which carries a substantial, life-long burden for the patient. Secukinumab is a fully human anti-interleukin-17A monoclonal antibody, approved in the USA and EU for the treatment of AS. In this narrative review, we searched PubMed with the aim of consolidating the recent literature regarding the impact of secukinumab on patient-reported outcomes in patients with AS. A large clinical trial program has demonstrated the efficacy of secukinumab in relieving the signs and symptoms of AS. Most importantly from a patient perspective, secukinumab has produced improvements in a range of patient-reported outcomes (PROs), including pain, fatigue, quality of life and work productivity, as well as composite measures including patient-reported elements, such as the Bath indices and Assessment of SpondyloArthritis international Society (ASAS) response criteria. Benefits to patients were rapid, and sustained in the long term (up to 5 years). The positive effect of secukinumab was seen regardless of whether patients had previously been treated with anti-tumor necrosis factor (TNF) therapies. Greater improvements in PROs were associated with patients being anti-TNF-naïve, of a younger age, with shorter disease duration and higher objective measures of inflammation at baseline. The available real-world evidence suggests that the effects of secukinumab on PROs in clinical practice are consistent with those seen in clinical trials, and evidence in a real-world setting continues to be collected.Keywords: ankylosing spondylitis, secukinumab, patient-reported outcomes
format	article
author	Tahir H Moorthy A Chan A
author_facet	Tahir H Moorthy A Chan A
author_sort	Tahir H
title	Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
title_short	Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
title_full	Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
title_fullStr	Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
title_full_unstemmed	Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
title_sort	impact of secukinumab on patient-reported outcomes in the treatment of ankylosing spondylitis: current perspectives
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8851a219e8d84ce2863bdcb761cfbb27
work_keys_str_mv	AT tahirh impactofsecukinumabonpatientreportedoutcomesinthetreatmentofankylosingspondylitiscurrentperspectives AT moorthya impactofsecukinumabonpatientreportedoutcomesinthetreatmentofankylosingspondylitiscurrentperspectives AT chana impactofsecukinumabonpatientreportedoutcomesinthetreatmentofankylosingspondylitiscurrentperspectives
_version_	1718395949408059392

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives

Ejemplares similares